PFIZER INC (PFE)
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
📈 **POSITIVE** • High confidence analysis (85%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business